Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond
Sarcomas gather a heterogeneous group of mesenchymal malignant tumors including more than 150 different subtypes. Most of them represent aggressive tumors with poor prognosis at the advanced stage, despite the better molecular characterization of these tumors and the development of molecular-driven...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/6/1643 |
| _version_ | 1797613018300809216 |
|---|---|
| author | Mina Fazel Armelle Dufresne Hélène Vanacker Waisse Waissi Jean-Yves Blay Mehdi Brahmi |
| author_facet | Mina Fazel Armelle Dufresne Hélène Vanacker Waisse Waissi Jean-Yves Blay Mehdi Brahmi |
| author_sort | Mina Fazel |
| collection | DOAJ |
| description | Sarcomas gather a heterogeneous group of mesenchymal malignant tumors including more than 150 different subtypes. Most of them represent aggressive tumors with poor prognosis at the advanced stage, despite the better molecular characterization of these tumors and the development of molecular-driven therapeutic strategies. During the last decade, immunotherapy has been developed to treat advanced cancers, mainly thanks to immune checkpoint inhibitors (ICI) such as anti-PD1/PDL1 and later to adoptive immune cell therapies. In this review, we aim to summarize the state of the art of immunotherapy in soft tissue sarcomas (STS). Overall, the clinical trials of ICI that included a wide diversity of STS subtypes reported limited efficacy with some outlying responders. Both emerging biomarkers are of interest in selecting good candidates and in the development of combination therapies. Finally, the recent breakthroughs of innovative adoptive therapies in STS seem highly promising. |
| first_indexed | 2024-03-11T06:50:02Z |
| format | Article |
| id | doaj.art-d43daff320bd4acbbf96da19d97c20e3 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T06:50:02Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-d43daff320bd4acbbf96da19d97c20e32023-11-17T10:05:10ZengMDPI AGCancers2072-66942023-03-01156164310.3390/cancers15061643Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and BeyondMina Fazel0Armelle Dufresne1Hélène Vanacker2Waisse Waissi3Jean-Yves Blay4Mehdi Brahmi5Centre Léon Bérard, 28 Rue Laënnec, 69008 Lyon, FranceCentre Léon Bérard, 28 Rue Laënnec, 69008 Lyon, FranceCentre Léon Bérard, 28 Rue Laënnec, 69008 Lyon, FranceCentre Léon Bérard, 28 Rue Laënnec, 69008 Lyon, FranceCentre Léon Bérard, 28 Rue Laënnec, 69008 Lyon, FranceCentre Léon Bérard, 28 Rue Laënnec, 69008 Lyon, FranceSarcomas gather a heterogeneous group of mesenchymal malignant tumors including more than 150 different subtypes. Most of them represent aggressive tumors with poor prognosis at the advanced stage, despite the better molecular characterization of these tumors and the development of molecular-driven therapeutic strategies. During the last decade, immunotherapy has been developed to treat advanced cancers, mainly thanks to immune checkpoint inhibitors (ICI) such as anti-PD1/PDL1 and later to adoptive immune cell therapies. In this review, we aim to summarize the state of the art of immunotherapy in soft tissue sarcomas (STS). Overall, the clinical trials of ICI that included a wide diversity of STS subtypes reported limited efficacy with some outlying responders. Both emerging biomarkers are of interest in selecting good candidates and in the development of combination therapies. Finally, the recent breakthroughs of innovative adoptive therapies in STS seem highly promising.https://www.mdpi.com/2072-6694/15/6/1643soft tissue sarcomasimmunotherapyimmune checkpoint blockadeadoptive T-cell therapies |
| spellingShingle | Mina Fazel Armelle Dufresne Hélène Vanacker Waisse Waissi Jean-Yves Blay Mehdi Brahmi Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond Cancers soft tissue sarcomas immunotherapy immune checkpoint blockade adoptive T-cell therapies |
| title | Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond |
| title_full | Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond |
| title_fullStr | Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond |
| title_full_unstemmed | Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond |
| title_short | Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond |
| title_sort | immunotherapy for soft tissue sarcomas anti pd1 pdl1 and beyond |
| topic | soft tissue sarcomas immunotherapy immune checkpoint blockade adoptive T-cell therapies |
| url | https://www.mdpi.com/2072-6694/15/6/1643 |
| work_keys_str_mv | AT minafazel immunotherapyforsofttissuesarcomasantipd1pdl1andbeyond AT armelledufresne immunotherapyforsofttissuesarcomasantipd1pdl1andbeyond AT helenevanacker immunotherapyforsofttissuesarcomasantipd1pdl1andbeyond AT waissewaissi immunotherapyforsofttissuesarcomasantipd1pdl1andbeyond AT jeanyvesblay immunotherapyforsofttissuesarcomasantipd1pdl1andbeyond AT mehdibrahmi immunotherapyforsofttissuesarcomasantipd1pdl1andbeyond |